



Pfizer Announces Conclusion of Consent Solicitation For \$22.5 Million of Debt

Monday, August 27, 2012 - 11:00pm

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the results of its solicitation of consents to amend certain provisions of the indentures with respect to the following outstanding debt securities of its wholly-owned subsidiary Pharmacia Corporation:

Debt Security CUSIP No.

Outstanding Principal Amount

6.47% Notes due 2018 61167HBK8 \$
20,000,000

8.70% Debentures due 2021 71713UAR3 \$ 2,507,000

Based on information provided by D.F. King & Co., Inc., the information and tabulation agent for the consent solicitation, as of 5:00 p.m., New York City time, on Monday, August 27, 2012, the required consents from holders of the \$20,000,000 outstanding aggregate principal amount of 6.47% Notes due 2018, CUSIP No. 61167HBK8, and outstanding aggregate principal amount of \$2,507,000 8.70% Debentures due 2021, CUSIP No. 71713UAR3 had not been received. Adoption of the proposed amendments required consent of holders of at least 662/3% in principal amount of each series of debt securities.

Because the required consents were not received, Pfizer will not make any consent payment in accordance with the terms of the consent solicitation.

Pfizer Inc: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pfizer Inc. Media Contact: Chris Loder, 212-733-7987 or Investor Contact: Suzanne Harnett, 212-733-8009